We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 77.51%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STML
76
DELISTED
Stemline Therapeutics, Inc.
STML
$3.92M 0.03%
333,497
– –
NDRM
77
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.84M 0.03%
250,000
– –
CRIS icon
78
Curis
CRIS
$3.83M
$3.57M 0.03%
+539
New +$3.24M
ENTA icon
79
Enanta Pharmaceuticals
ENTA
$392M
$3.39M 0.03%
75,357
– –
ITCI
80
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.33M 0.03%
104,166
– –
IONS icon
81
Ionis Pharmaceuticals
IONS
$9.93B
$3.29M 0.03%
57,140
– –
TARA icon
82
Protara Therapeutics
TARA
$228M
$3.16M 0.03%
4,419
+96
+2% +$59.4K
IMDZ
83
DELISTED
Immune Design Corp.
IMDZ
$3.08M 0.03%
+148,937
New +$3.52M
BLPH
84
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$2.78M 0.02%
23,333
– –
VTAE
85
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.7M 0.02%
187,597
– –
WINT
86
DELISTED
Windtree Therapeutics Inc
WINT
$2.43M 0.02%
254,975
– –
MRNS
87
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.32M 0.02%
50,000
– –
SVRA icon
88
Savara
SVRA
$1.15B
$2.31M 0.02%
67,249
– –
TCRT icon
89
Alaunos Therapeutics
TCRT
$4.47M
$2.27M 0.02%
1,262
– –
ABUS icon
90
Arbutus Biopharma
ABUS
$1.03B
$2.14M 0.02%
180,582
– –
AUPH icon
91
Aurinia Pharmaceuticals
AUPH
$2.22B
$2.13M 0.02%
711,499
– –
IRWD icon
92
Ironwood Pharmaceuticals
IRWD
$709M
$2.04M 0.02%
201,981
– –
ISEE
93
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.86M 0.02%
35,649
– –
ADAP
94
DELISTED
Adaptimmune Therapeutics
ADAP
$1.83M 0.02%
+100,000
New +$1.72M
PTN
95
Palatin Technologies
PTN
$17.2M
$1.82M 0.02%
1,640
– –
CLLS
96
Cellectis
CLLS
$342M
$1.8M 0.02%
50,000
– –
LOXO
97
DELISTED
Loxo Oncology, Inc
LOXO
$1.8M 0.02%
100,000
– –
AIXC
98
AIxCrypto Holdings Inc
AIXC
$22.7M
$1.78M 0.02%
+3
New +$1.75M
ASND icon
99
Ascendis Pharma A/S
ASND
$16.6B
$1.77M 0.02%
100,000
– –
DERM
100
DELISTED
Dermira, Inc.
DERM
$1.75M 0.02%
100,000
– –
2 3
4
5 6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2015 Portfolio in Review

As of Q2 2015, Julian Baker held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Julian Baker withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 46% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Julian Baker's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Julian Baker added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Julian Baker's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Julian Baker fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Julian Baker's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Julian Baker opened 10 new positions and closed 12 in Q2 2015.
  • Julian Baker's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.